About: retinalconsultantsaz.com

Posts by retinalconsultantsaz.com:

Pravin U. Dugel, MD: Clinical Effectiveness of Switching Between Ranibizumab and Aflibercept in Treatment of Neovascular AMD: US Real-World Outcomes

Purpose: The purpose of this article is to examine visual acuity (VA) outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes switching between ranibizumab and aflibercept in routine clinical practice. Methods: Electronic medical records were used to identify nAMD eyes receiving ranibizumab or aflibercept with 12 months’ follow-up since switching antivascular endothelial growth… Read More »


Dr. Pravin U. Dugel – HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration

Pravin U. Dugel, Adrian Koh, Yuichiro Ogura, Glenn Jaffe, Ursula Schmidt-Erfurth, David Brown, Andre V. Gomes, James Warburton, Andreas Weichselberger, Frank G. Holz Abstract ObjectiveTwo similarly designed, phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (AMD). DesignDouble-masked, multicenter, active-controlled, randomized trials. Patients(N = 1817) with untreated,… Read More »


Pravin Dugel, MD, joins Ross Lakhanpal, MD, to define, discuss, and forecast the future of informatics in retina. VBS 2019

Pravin Dugel, MD, R. Ross Lakhanpal, MD   Channels: Retina | Posted 4/5/2019 Pravin Dugel, MD, joins Ross Lakhanpal, MD, to define, discuss, and forecast the future of informatics in retina. In Dr. Dugel’s view, the informatics platforms used in other fields could translate to retina and, when they arrive, will change the preparation and… Read More »


Dr. Pravin U. Dugel Chairs Retina World Congress Unplugged

RWC Unplugged offers participants a unique opportunity to learn, share and discuss controversial topics in retina with a large group of industry experts and clinical leaders. With no scripts or industry commercials, this event evokes deep discussions moderated by KOLs, who encourage attendees to challenge their perspectives in lively, no-holds-barred discussions, with live polling on… Read More »


Positive preliminary data in US retinal trial: Significant improvement in vision in first cohort of Phase II subjects in US trial of hRPC cell therapy in retinitis pigmentosa

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with the ongoing Phase I/II clinical trial of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP). The Company is pleased to report that all three of the first… Read More »


Dr. Pravin U. Dugel Invited to Speak at First Gene Therapy for Chronic Retinal Diseases Summit in New York

ROCKVILLE, Md., Feb. 14, 2019 /PRNewswire/ — REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, will host an analyst and investor event focused on its ophthalmology program, including its lead product candidate RGX-314, on Thursday, February 21,… Read More »


Dr. Derek Kunimoto: Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States

Derek Kunimoto, MD, JD; Masahito Ohji, MD; Raj K. Maturi, MD; Tetsuju Sekiryu, MD; Ying Wang, MD, PhD; Grace Pan, MS; Xiao-Yan Li, MD; Susan Schneider, MD; for the BAMBOO and CYPRESS Study Groups  BACKGROUND AND OBJECTIVE: To evaluate comparability of abicipar pegol (abicipar) effects in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) in… Read More »


Dr. Pravin U. Dugel – First Patients in Arizona Receive Experimental Stem Cell Treatment for Eye Disease

PHOENIX (Feb. 11, 2019)– Retinal Consultants of Arizona & the Retinal Research Institute – one of the nation’s leading retina & vitreous clinical research and patient treatment facilities – is proud to announce that Dr. Pravin U. Dugel has conducted the first stem cell therapy treatment for patients with retinitis pigmentosa (RP) in Arizona. The… Read More »


Graybug Vision Presents Top Line Results Of Phase 1/2a ADAGIO Study At Hawaiian Eye & Retina 2019

Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019 ADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF receptors for the treatment… Read More »


Pravin U. Dugel, MD: Association Between Early Anatomic Responses to Anti-Vascular Endothelial Growth Factor Therapy and Long-term Outcome in Diabetic Macular Edema

An Independent Analysis of Protocol i Study Data Dugel, Pravin U., MD*,†; Campbell, Joanna H., PhD‡; Kiss, Szilárd, MD§; Loewenstein, Anat, MD¶; Shih, Vanessa, PharmD‡; Xu, Xiaoshu, MS‡; Holekamp, Nancy M., MD**; Augustin, Albert J., MD, PhD††; Ho, Allen C., MD‡‡; Gonzalez, Victor H., MD§§; Whitcup, Scott M., MD¶¶ RETINA: January 2019 – Volume 39… Read More »


© 2019 Retinal Consultants of Arizona. All Rights Reserved.
~ Design and Development by Advice Media | MedNet